Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma

Severe eosinophilic asthma (SEA) is associated with high peripheral blood and airway eosinophilia, recurrent disease exacerbations and severe airflow limitation. Eosinophilic inflammation is also responsible for small airway disease (SAD) development. SEA patients experience poor disease control and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biomedicines
Principais autores: Angelantonio Maglio, Carolina Vitale, Simona Pellegrino, Cecilia Calabrese, Maria D’Amato, Antonio Molino, Corrado Pelaia, Massimo Triggiani, Girolamo Pelaia, Cristiana Stellato, Alessandro Vatrella
Formato: Artigo
Publicado em: MDPI AG 2021-10-01
Assuntos:
Severe asthma
Mepolizumab
Eosinophils
Lung function
FEF25-75
ACT
Acesso em linha:https://www.mdpi.com/2227-9059/9/11/1550
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

https://www.mdpi.com/2227-9059/9/11/1550

Registros relacionados